Now Reading: USFDA issues three observations to Aurobindo Pharma arm in Andhra
-
01
USFDA issues three observations to Aurobindo Pharma arm in Andhra
Aurobindo Pharma on Friday said the US health regulator has issued three observations after inspecting a facility of its subsidiary in Andhra Pradesh. The United States Food and Drug Administration (USFDA) inspected…
Aurobindo Pharma on Friday said the US health regulator has issued three observations after inspecting a facility of its subsidiary in Andhra Pradesh. The United States Food and Drug Administration (USFDA) inspected Unit-VI, an API manufacturing facility of Apitoria Pharma Pvt Ltd, at E-Bonangi Village in Anakapalli district, from August 24 to 28.
The company said in a regulatory filing that the inspection concluded with three observations which are procedural in nature. Aurobindo Pharma said it will respond to the USFDA within the stipulated timeline and is committed to maintaining robust quality and compliance standards across its manufacturing facilities.
Indian Opinion Analysis
USFDA observations classified as procedural typically do not trigger immediate regulatory action, such as an import alert or warning letter, unless the company fails to respond adequately. Aurobindo Pharma has faced USFDA scrutiny at multiple facilities in recent years, and any escalation at Unit-VI could affect its API exports to the US market, a key revenue stream. The company now has 15 working days to submit a corrective response. The regulator will then decide whether the response closes the matter or warrants a re-inspection.
Source: ndtvprofit.com
This brief was synthesised by AI from the source linked above.
